BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35928898)

  • 1. Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression.
    Demarchi G; Perrone S; Esper Romero G; De Bonis C; Casasco JP; Sevlever G; Berner SI; Cristina C
    Front Endocrinol (Lausanne); 2022; 13():870172. PubMed ID: 35928898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
    Yamamoto M; Nakao T; Ogawa W; Fukuoka H
    Front Endocrinol (Lausanne); 2021; 12():650791. PubMed ID: 34220707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.
    Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Pękul M; Zieliński G; Styk A; Kunicki J; Działach Ł; Witek P; Bujko M
    Front Endocrinol (Lausanne); 2023; 14():1124646. PubMed ID: 37065760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, Laboratory, and Treatment Profiles of Silent Corticotroph Adenomas That Have Transformed to the Functional Type: A Case Series With a Literature Review.
    Zheng G; Lu L; Zhu H; You H; Feng M; Liu X; Dai C; Yao Y; Wang R; Zhang H; Sun X; Lu Z
    Front Endocrinol (Lausanne); 2020; 11():558593. PubMed ID: 33071973
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide.
    Tanaka S; Yamamoto M; Morita M; Takeno A; Kanazawa I; Yamaguchi T; Yamada S; Inoshita N; Oki Y; Kurosaki M; Sugimoto T
    Endocr J; 2019 Aug; 66(8):701-708. PubMed ID: 31130573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, Biological, Radiological Pathological and Immediate Post-Operative Remission of Sparsely and Densely Granulated Corticotroph Pituitary Tumors: A Retrospective Study of a Cohort of 277 Patients With Cushing's Disease.
    Rak B; Maksymowicz M; Pękul M; Zieliński G
    Front Endocrinol (Lausanne); 2021; 12():672178. PubMed ID: 34135861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin suppresses growth and adrenocorticotrophic hormone secretion in mouse pituitary corticotroph tumor AtT20 cells.
    Jin K; Ruan L; Pu J; Zhong A; Wang F; Tan S; Huang H; Mu J; Yang G
    Mol Cell Endocrinol; 2018 Dec; 478():53-61. PubMed ID: 30025915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why don't corticotroph tumors always produce Cushing's disease?
    García-Martínez A; Cano DA; Flores-Martínez A; Gil J; Puig-Domingo M; Webb SM; Soto-Moreno A; Picó A
    Eur J Endocrinol; 2019 Sep; 181(3):351-361. PubMed ID: 31319379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggressive corticotroph tumors and carcinomas.
    Lasolle H; Vasiljevic A; Jouanneau E; Ilie MD; Raverot G
    J Neuroendocrinol; 2022 Aug; 34(8):e13169. PubMed ID: 35979732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
    Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
    Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models.
    Demarchi G; Valla S; Perrone S; Chimento A; Bonadeo N; Vitale DL; Spinelli FM; Cervio A; Sevlever G; Alaniz L; Berner S; Cristina C
    Tumour Biol; 2022; 44(1):85-105. PubMed ID: 35811548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
    Katznelson L; Bogan JS; Trob JR; Schoenfeld DA; Hedley-Whyte ET; Hsu DW; Zervas NT; Swearingen B; Sleeper M; Klibanski A
    J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of silent corticotroph pituitary neuroendocrine tumors (PitNETs) from non-functioning PitNETs using kinetic analysis of dynamic MRI.
    Amano T; Masumoto T; Watanabe D; Hoshiai S; Mori K; Sakamoto N; Kino H; Akutsu H; Nakajima T
    Jpn J Radiol; 2023 Sep; 41(9):938-946. PubMed ID: 37027094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gamma knife radiosurgery in patients with Cushing's disease: Comparison of aggressive pituitary corticotroph tumor versus corticotroph adenoma.
    Kara M; Güdük M; Samanci Y; Yilmaz M; Şengöz M; Peker S
    Clin Neurol Neurosurg; 2020 Oct; 197():106151. PubMed ID: 32882541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor.
    Nakano-Tateno T; Satou M; Inoshita N; van Landeghem FKH; Easaw J; Mehta V; Tateno T; Chik CL
    Endocr Pathol; 2021 Sep; 32(3):418-426. PubMed ID: 32833164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
    Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
    Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently.
    Bradley KJ; Wass JA; Turner HE
    Clin Endocrinol (Oxf); 2003 Jan; 58(1):59-64. PubMed ID: 12519413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
    Dai C; Liang S; Sun B; Kang J
    Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic correlations of silent corticotroph adenomas of the pituitary: report of four cases and literature review.
    Sahli R; Christ ER; Seiler R; Kappeler A; Vajtai I
    Pathol Res Pract; 2006; 202(6):457-64. PubMed ID: 16497445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathology and pathogenesis of pituitary corticotroph adenoma].
    Trouillas J
    Neurochirurgie; 2002 May; 48(2-3 Pt 2):149-62. PubMed ID: 12058122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.